MedTrace Logo

China Gender-affirming Hormone Therapy Study

NCT05318755 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2024-11-07

No results posted yet for this study

Summary

Data about transgender medical care, especially the gender-affirming hormone therapy (GAHT) is extremely insufficient in China. Few evidence exists in the physical and psychological effects of the hormonal treatment in Chinese transgender population. CGAHT is designed to describe the social and mental condition of transgender people who are seeking for formal GAHT, and to investigate the physical and psychological effects of GAHT on this population in China.

Conditions

Interventions

DRUG

GAHT for transgender men

Testosterone undecanoate

DRUG

GAHT for transgender women

Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)

Sponsors & Collaborators

  • Tsinghua University

    collaborator OTHER

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Tianpei Hong, PhD., M.D. · Department of Endocrinology and Metabolism, Peking University Third Hospital

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-16
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05318755 on ClinicalTrials.gov